Radiopharm Theranostics Limited (RADX)
NASDAQ: RADX · Real-Time Price · USD
4.580
-0.060 (-1.29%)
May 20, 2026, 4:00 PM EDT - Market closed
Radiopharm Theranostics Revenue
Radiopharm Theranostics had revenue of 6.20M AUD in the half year ending December 31, 2025, with 52.60% growth. This brings the company's revenue in the last twelve months to 16.28M, up 4,823.49% year-over-year. In the fiscal year ending June 30, 2025, Radiopharm Theranostics had annual revenue of 12.51M with 538.86% growth.
Revenue (ttm)
16.28M AUD
Revenue Growth
+4,823.49%
P/S Ratio
4.91
Revenue / Employee
1,162,745 AUD
Employees
14
Market Cap
53.30M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 12.51M | 10.55M | 538.86% |
| Jun 30, 2024 | 1.96M | -4.25M | -68.46% |
| Jun 30, 2023 | 6.21M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 55.54M |
| Xilio Therapeutics | 53.48M |
| Metagenomi Therapeutics | 22.33M |
| Hyperion DeFi | 1.04M |
| aTyr Pharma | 190.00K |
RADX News
- 22 days ago - Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference - Transcripts
- 22 days ago - Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference - Filings
- 22 days ago - Radiopharm Theranostics Transcript: Deutsche Bank ADR Virtual Investor Conference - Transcripts
- 22 days ago - Radiopharm Theranostics Slides: Deutsche Bank ADR Virtual Investor Conference - Filings
- 27 days ago - Radiopharm Theranostics Reports Business Update - GlobeNewsWire
- 4 weeks ago - Radiopharm Theranostics Earnings release: Q3 2026 - Filings
- 4 weeks ago - Radiopharm Theranostics Earnings release: Q3 2026 - Filings
- 4 weeks ago - Radiopharm announces new data from Phase 0/1 HEAT trial - TheFly